Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Atorvastatin affects C-reactive protein levels in patients with coronary artery disease
SUMMARY Background : Elevated levels of C-reactive protein ( CRP ) are considered to be one of the indicators of poor prognosis in coronary artery disease ( CAD ) . The aim of this study was to evaluate anti-inflammatory effects of atorvastatin in patients with CAD by measuring serum CRP levels . Methods : After measuring the baseline levels of CRP and lipid fractions , the patients were divided into two groups . In Group A ( n = 46 ) , atorvastatin ( 20 mg/day ) was administered in addition to classic antianginal treatment ( beta-blocker , nitrate and aspirin ) . In Group B ( n = 32 ) , the usual antianginal treatment was continued . Following 4 weeks of treatment the same measurements were repeated . Results : In Group A , CRP decreased from 20.3 mg/dl ( 95 % CI , 9 - 31.8 ) to 10.8 mg/dl ( 95 % CI , 2.7 - 18.9 ) ( p < 0.001 ) . In Group B , CRP decreased from 17 mg/dl ( 95 % CI , 13.1 - 21 ) to 12.8 mg/dl ( 95 % CI , 9.7 - 15.9 ) ( p < 0.01 ) . The decrease in group A was more than in group B ( p = 0.003 ) . Conclusions : In patients with CAD , atorvastatin exerted an anti-inflammatory effect represented by decreasing CRP levels . This effect was independent of the change in low density lipoprotein cholesterol ( LDL-C ) or high density lipoprotein cholesterol ( HDL-C ) levels
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .